
CLAIMS

~~What is claimed is:~~

1. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a dengue virus (DENV) infection in a human subject, wherein the pharmaceutical composition is useful for~~comprising~~:

a) administering to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (I)~~, or a pharmaceutical composition comprising a compound of Formula (I)~~, within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to the human subject a dose of about 25 to about 300 mg of a compound of Formula (I), ~~or a pharmaceutical composition comprising a compound of Formula (I),~~ at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,



(I),

or a pharmaceutically acceptable salt thereof;


wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

2. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a secondary dengue infection in a human subject, wherein the pharmaceutical composition is useful for~~comprising~~:

a) administering to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (I), ~~or a pharmaceutical composition~~

~~comprising a compound of Formula (I),~~ within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to the human subject a dose of about 25 to about 300 mg of a compound of Formula (I), ~~or a pharmaceutical composition comprising a compound of Formula (I),~~ at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,




(I),

or a pharmaceutically acceptable salt thereof;

wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

3. The ~~method~~ use of Claim 1 or Claim 2, wherein the compound of Formula (I), is a compound of Formula (II):




(II),

or a pharmaceutically acceptable salt thereof.

4. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a dengue virus (DENV) infection in a human subject, wherein the pharmaceutical composition is useful for ~~comprising~~:

a) administering to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (II), or a pharmaceutical composition comprising a compound of Formula (II), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to the human subject a dose of about 25 to about 300 mg of a compound of Formula (II), or a pharmaceutical composition comprising a compound of Formula (II), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (II) having the following structure,




(II),

or a pharmaceutically acceptable salt thereof.

5. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a dengue virus (DENV) infection in a human subject, wherein the pharmaceutical composition is in oral form and is useful for~~comprising~~:

a) administering orally to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering orally to the human subject a dose of about 25 to about 300 mg of a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,



(I),


or a pharmaceutically acceptable salt thereof;

wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

6. Use of a compound of Formula (III) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a dengue virus (DENV) infection in a human subject, wherein the pharmaceutical composition is useful for~~comprising~~:

a) administering to the human subject an initial dose of about 100 to about 600 mg of a compound of Formula (III), or a pharmaceutical composition comprising a compound of Formula (III), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to the human subject a dose of about 25 to about 300 mg of a compound of Formula (III), or a pharmaceutical composition comprising a compound of Formula (III), at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (III) having the following structure,



(III),

or a pharmaceutically acceptable salt thereof;

wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

7. The use according to any one of claims 1 to 6, wherein the pharmaceutical composition is in dose(s) from about 25mg to about 600mg of a compound of Formula (I), the compound of Formula (II) or the compound of Formula (III).

~~7.~~8. The ~~method~~ use of any one of Claims 1-~~6~~7, wherein the human subject is an adult or a child.

~~8.~~9. The ~~method~~ use of any one of Claims 1-~~6~~7, wherein the compound of Formula (I), the compound of Formula (II), or the compound of Formula (III) is converted to castanospermine after administration to a human subject.

~~9.~~10. The ~~method~~ use of any one of Claims 1-~~8~~9, wherein a steady state Cmin serum or plasma concentration of between about 0.05 and about 2.0 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.

~~10.~~11. The ~~method~~ use of any one of Claims 1-~~8~~9, wherein a steady state Cmin serum or plasma concentration of between about 1.0 and about 2.0 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.

~~11.~~12. The ~~method~~ use of any one of Claims 1-~~8~~9, wherein a steady state Cmin serum or plasma concentration of between about 1.0 and about 1.5 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.

~~12.~~13. The ~~method~~ use of any one of Claims 1-~~8~~9, wherein a steady state Cmin serum or plasma concentration of between about 1.5 and about 2.0 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.

~~13.~~14. The ~~method~~ use of any one of Claims 1-~~8~~9, wherein a steady state Cmin serum or plasma concentration of between about 1.25 and about 1.75 microgram/mL of castanospermine in an adult or child human subject is attained after treatment.

~~14.~~15. The ~~method~~ use of any one of Claims 1-~~13~~14, wherein dengue viral infection comprises at least one dengue virus selected from DENV1, DENV2, DENV3 and DENV4.

~~15.~~16. The ~~method~~ use of any one of Claims 1 and 4-~~14~~15, wherein the dengue viral infection is secondary dengue infection.

~~16.~~17. The ~~method~~ use of any one of Claims 1-~~15~~16, wherein the human subject to be treated is positive prior to treatment for a dengue infection using a NS1 strip assay or quantitative PCR.

~~17.~~18. The ~~method~~ use of any one of Claims 1-~~16~~17, wherein the virological log reduction in treated human subjects is at least 50% greater than untreated or placebo-treated groups.

~~18.~~19. The ~~method~~ use of any one of Claims 1-~~17~~18, wherein administering the ~~compound, or the~~ pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 0.05 and about 2.0 microgram/mL of castanospermine.

~~19.~~20. The ~~method~~ use of any one of Claims 1-~~17~~18, wherein administering the ~~compound, or the~~ pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 1.0 and about 2.0 microgram/mL of castanospermine.

~~20.~~21. The ~~method~~ use of any one of Claims 1-~~17~~18, wherein administering the ~~compound, or the~~ pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 1.0 and about 1.5 microgram/mL of castanospermine.

~~21.~~22. The ~~method~~ use of any one of Claims 1-~~17~~18, wherein administering the ~~compound, or the~~ pharmaceutical composition, achieves a steady state Cmin serum or plasma concentration of between about 1.5 and about 2.0 microgram/mL of castanospermine.

~~22.~~23. The ~~method~~ use of any one of Claims 1-~~17~~18, wherein administering the ~~compound, or the~~ pharmaceutical composition, achieves a steady state Cmin serum or plasma

concentration of between about 1.25 and about 1.75 microgram/mL of castanospermine.

~~23.~~24. The ~~method~~ use of any one of Claims 1-4 and 6-~~22~~23, wherein the ~~compound, or the~~ pharmaceutical composition, is for ~~administered~~ intravenous~~ly~~, oral~~ly~~, rectal~~ly~~, or sublingual~~ly~~ administration.

~~24.~~25. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered an initial dose of 150 mg and a dose of 100 mg is thereafter administered to the human subject every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~25.~~26. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to the human subject every 6 hours for about 1 day, about 2 days, or about 5 days.

~~26.~~27. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to the human subject every 8 hours for about 1 day, about 2 days, or about 5 days.

~~27.~~28. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to the human subject every 12 hours for about 1 day, about 2 days, or about 5 days.

~~28.~~29. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered an initial dose of 150 mg and a dose of 200 mg is thereafter administered to the human subject every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~29.~~30. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered an initial dose of 200 mg and a dose of 100 mg is thereafter

administered to the human subject every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~30.~~31. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered an initial dose of 200 mg and a dose of 150 mg is thereafter administered to the human subject every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~31.~~32. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered an initial dose of 200 mg and a dose of 200 mg is thereafter administered to the human subject every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.


~~32.~~33. The ~~method~~ use of any one of Claims 1-~~23~~24, wherein the human subject is administered a single or a divided dose of about 25 to about 300 mg of the compound or the pharmaceutical composition, for about between about 5 days to about 10 days.

~~33.~~34. The ~~method~~ use of Claim ~~32~~33, wherein the human subject is administered a divided dose of about 25 to about 300 mg of the compound, or the pharmaceutical composition, for about between about 5 days to about 10 days.

~~34.~~35. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a dengue virus (DENV) infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for ~~comprising~~:

a) administering to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (I), ~~or a pharmaceutical composition comprising a compound of Formula (I),~~ within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (I), ~~or a pharmaceutical composition comprising a compound of Formula (I),~~ at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,



(I),


or a pharmaceutically acceptable salt thereof;

wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

~~35.~~36. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a secondary dengue infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for~~comprising~~:

a) administering to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (I), ~~or a pharmaceutical composition comprising a compound of Formula (I),~~ within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (I), ~~or a pharmaceutical composition comprising a compound of Formula (I),~~ at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,




(I),

or a pharmaceutically acceptable salt thereof;

wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

~~36.~~37. The ~~method~~ use of Claim ~~34~~ 35 or Claim ~~35~~36, wherein the compound of Formula (I), is a compound of Formula (II):




(II),

or a pharmaceutically acceptable salt thereof.

~~37.~~38. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a dengue virus (DENV) infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for~~comprising~~:

a) administering to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (II), ~~or a pharmaceutical composition comprising a compound of Formula (II),~~ within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (II), ~~or a pharmaceutical composition comprising a compound of Formula (II),~~ at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (II) having the following structure,




(II),

or a pharmaceutically acceptable salt thereof.

~~38.~~39. Use of a compound of Formula (I) in the preparation of a pharmaceutical composition in the preparation of a pharmaceutical composition for ~~A method of~~ treating a dengue virus (DENV) infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for~~comprising~~:

a) administering orally to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (I), ~~or a pharmaceutical composition comprising a compound of Formula (I),~~ within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering orally to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (I), ~~or a pharmaceutical composition comprising a compound of Formula (I),~~ at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (I) having the following structure,



(I),


or a pharmaceutically acceptable salt thereof;

wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

~~39.~~40. Use of a compound of Formula (III) in the preparation of a pharmaceutical composition for ~~A method of~~ treating a dengue virus (DENV) infection in a plurality of human subjects, wherein the pharmaceutical composition is useful for~~comprising~~:

a) administering to each of the plurality of human subjects an initial dose of about 100 to about 600 mg of a compound of Formula (III), ~~or a pharmaceutical composition comprising a compound of Formula (III),~~ within from about onset of fever to about 72 hours of fever onset due to dengue infection; and

b) administering to each of the plurality of human subjects a dose of about 25 to about 300 mg of a compound of Formula (III), ~~or a pharmaceutical composition comprising a compound of Formula (III),~~ at intervals of from about 6 to about 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (III) having the following structure,



(III),

or a pharmaceutically acceptable salt thereof;

wherein R^1, R^2, and R^3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

41. The use according to any one of claims 35 to 40, wherein the pharmaceutical composition is in dose(s) from about 25mg to about 600mg of a compound of Formula (I), the compound of Formula (II) or the compound of Formula (III).

~~40.~~42. The ~~method~~ use of any one of Claims ~~34-39~~35-41, wherein the plurality of human subjects includes adults and/or children.

41.43. The ~~method~~ use of any one of Claims ~~34-39~~35-41, wherein the compound of Formula (I), the compound of Formula (II), or the compound of Formula (III) is converted to castanospermine after administration to each of the plurality of human subjects.

42.44. The ~~method~~ use of any one of Claims ~~34-41~~35-41, wherein an average steady state Cmin serum or plasma concentration of between about 0.05 and about 2.0 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.

43.45. The ~~method~~ use of any one of Claims ~~34-41~~35-41, wherein an average steady state Cmin serum or plasma concentration of between about 1.0 and about 2.0 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.

44.46. The ~~method~~ use of any one of Claims ~~34-41~~35-41, wherein an average steady state Cmin serum or plasma concentration of between about 1.0 and about 1.5 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.

45.47. The ~~method~~ use of any one of Claims ~~34-41~~35-41, wherein an average steady state Cmin serum or plasma concentration of between about 1.5 and about 2.0 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.

46.48. The ~~method~~ use of any one of Claims ~~34-41~~35-41, wherein an average steady state Cmin serum or plasma concentration of between about 1.25 and about 1.75 microgram/mL of castanospermine in the plurality of human subjects is attained after treatment.

47.49. The ~~method~~ use of any one of Claims ~~34-46~~35-41, wherein dengue viral infection comprises at least one dengue virus selected from DENV1, DENV2, DENV3 and DENV4.

~~48.~~50. The ~~method~~ use of any one of Claims ~~34~~ 35 and ~~37-47~~38-49, wherein the dengue viral infection is secondary dengue infection.

~~49.~~51. The ~~method~~ use of any one of Claims ~~34-48~~35-50, wherein each of the plurality of human subjects to be treated is positive prior to treatment for a dengue infection using a NS1 strip assay or quantitative PCR.

~~50.~~52. The ~~method~~ use of any one of Claims ~~34-49~~35-51, wherein the virological log reduction in treated plurality of human subjects is at least 50% greater than untreated or placebo-treated groups.

~~51.~~53. The ~~method~~ use of any one of Claims ~~34-50~~35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma concentration in the plurality of human subjects of between about 0.05 and about 2.0 microgram/mL of castanospermine.

~~52.~~54. The ~~method~~ use of any one of Claims ~~34-50~~35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma concentration in the plurality of human subjects of between about 1.0 and about 2.0 microgram/mL of castanospermine.

~~53.~~55. The ~~method~~ use of any one of Claims ~~34-50~~35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma concentration in the plurality of human subjects of between about 1.0 and about 1.5 microgram/mL of castanospermine.

~~54.~~56. The ~~method~~ use of any one of Claims ~~34-50~~35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin serum or plasma concentration in the plurality of human subjects of between about 1.5 and about 2.0 microgram/mL of castanospermine.

~~55.~~57. The ~~method~~ use of any one of Claims ~~34-50~~35-52, wherein administering the compound, or the pharmaceutical composition, achieves an average steady state Cmin

serum or plasma concentration in the plurality of human subjects of between about 1.25 and about 1.5 microgram/mL of castanospermine.

~~56.~~58. The ~~method~~ use of any one of Claims ~~34-37~~35-38 and ~~39-55~~40-57, wherein the compound, or the pharmaceutical composition, is administered intravenously, orally, rectally, or sublingually.

~~57.~~59. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered an initial dose of 150 mg and a dose of 100 mg is thereafter administered to each of the plurality of human subjects every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~58.~~60. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to each of the plurality of human subjects every 6 hours for about 1 day, about 2 days, or about 5 days.

~~59.~~61. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to each of the plurality of human subjects every 8 hours for about 1 day, about 2 days, or about 5 days.

~~60.~~62. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to each of the plurality of human subjects every 12 hours for about 1 day, about 2 days, or about 5 days.

~~61.~~63. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered an initial dose of 150 mg and a dose of 200 mg is thereafter administered to each of the plurality of human subjects every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~62.~~64. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered an initial dose of 200 mg and a dose of 100 mg is

thereafter administered to each of the plurality of human subjects every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~63.~~65. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered an initial dose of 200 mg and a dose of 150 mg is thereafter administered to each of the plurality of human subjects every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~64.~~66. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered an initial dose of 200 mg and a dose of 200 mg is thereafter administered to each of the plurality of human subjects every 6 hours, 8 hours, or 12 hours for about 1 day, about 2 days, or about 5 days.

~~65.~~67. The ~~method~~ use of any one of Claims ~~34-56~~35-58, wherein each of the plurality of human subjects is administered a single or a divided dose of about 25 to about 300 mg of the compound or the pharmaceutical composition, for about between about 5 days to about 10 days.

~~66.~~68. The ~~method~~ use of Claim ~~65~~67, wherein each of the plurality of human subjects is administered a divided dose of about 25 to about 300 mg of the compound, or the pharmaceutical composition, for about between about 5 days to about 10 days.